Expression and function of ABCG2 and XIAP in glioblastomas.

Document Type


Publication Date



MMCRI, Pathology, Neurology

Journal Title

Journal of neuro-oncology.

MeSH Headings

ATP Binding Cassette Transporter, Subfamily G, Member 2, Adult, Aged, Aged, 80 and over, Animals, Antineoplastic Agents, Brain Neoplasms, Cells, Cultured, Dacarbazine, Diketopiperazines, Female, Follow-Up Studies, Glioblastoma, Heterocyclic Compounds, 4 or More Rings, Humans, Indoles, Male, Mice, Inbred NOD, Mice, Knockout, Mice, SCID, Middle Aged, Neoplasm Proteins, Neoplasm Transplantation, Neoplastic Stem Cells, Temozolomide, X-Linked Inhibitor of Apoptosis Protein


Despite multimodal treatment that includes surgery, radiation and chemotherapy, virtually all glioblastomas (GBM) recur, indicating that these interventions are insufficient to eradicate all malignant cells. To identify potential new therapeutic targets in GBMs, we examined the expression and function of proteins that are associated with therapy resistance and cancer cell survival. We measured the expression of eight such proteins in 50 GBM samples by immunohistochemistry and analyzed patient survival. We report that GBM patients with high expression of ABCG2 (also called BCRP) or XIAP at the protein level had worse survival than those with low expression. The adjusted hazard ratio for ABCG2 was 2.35 and for XIAP was 2.65. Since glioma stem cells (GSCs) have been shown to be more resistant than bulk tumor cells to anti-cancer therapies and to express high levels of these proteins, we also sought to determine if ABCG2 and XIAP have functional roles in GSCs. We used small molecule inhibitors to treat patient-derived GBM tumorspheres in vitro and observed that inhibitors of ABCG2, Ko143 and fumitremorgin, significantly reduced self-renewal. These results suggest that ABCG2 and XIAP proteins may be useful indicators of patient survival and that inhibition of ABCG2 may be a promising therapeutic strategy in GBMs.



First Page


Last Page